LEAWOOD, Kan., Nov. 10, 2017 /PRNewswire/ -- Elanco Animal
Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana
Therapeutics, Inc. (NASDAQ: PETX), today announced the European
Medicine Agency's (EMA) Committee for Medicinal Products for
Veterinary Use (CVMP) adopted a positive opinion to recommend the
marketing authorization of GALLIPRANT® (grapiprant
tablets) in the European Union. Following the positive opinion, the
European Commission will complete the regulatory process for a
final decision on the Marketing Authorisation in early
2018.
Galliprant is a first-in-class veterinary medicine that will be
indicated for the treatment of pain associated with mild to
moderate osteoarthritis in dogs. Grapiprant, the active ingredient
in Galliprant, is a non-steroidal non-cyclooxygenase
inhibiting anti-inflammatory drug. Elanco has exclusive rights to
develop, manufacture, market and commercialize Galliprant globally,
and it co-promotes the product with Aratana in the United States.
About Elanco Animal Health
Elanco provides
comprehensive products and knowledge services to improve animal
health and food-animal production in more than 70 countries around
the world. We value innovation, both in scientific research and
daily operations, and strive to cultivate a collaborative work
environment for more than 6,500 employees worldwide. Together with
our customers, we are committed to raising awareness about global
food security, and celebrating and supporting the human-animal
bond. Founded in 1954, Elanco is a division of Eli Lilly and
Company. Our worldwide headquarters and research facilities are
located in Greenfield, Indiana
(U.S.). Visit us at www.elanco.com or
www.elancoeurope.com.
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative therapeutics for dogs and cats. Aratana
believes that it can leverage the investment in the human
biopharmaceutical industry to bring therapeutics to dogs and cats
in a capital and time efficient manner. The company's pipeline
includes therapeutic candidates for the potential treatment of
pain, inappetence, viral diseases, allergy, cancer and other
serious medical conditions. Aratana believes the development and
commercialization of these therapeutics will permit veterinarians
and pet owners to manage pets' medical needs safely and
effectively, resulting in longer and improved quality of life for
pets. For more information, please visit www.aratana.com.
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995) about Galliprant, and reflects Lilly, Elanco's and
Aratana's current beliefs. However, as with any pharmaceutical
product, there are substantial risks and uncertainties in the
process of development and commercialization. Among other things,
there can be no guarantee that Galliprant will be commercially
successful. For further discussion of these and other risks and
uncertainties, see Lilly's and Aratana's most recent Form 10-K and
Form 10-Q filings with the United States Securities and Exchange
Commission, respectively. Except as required by law, Elanco and
Aratana undertakes no duty to update forward-looking statements to
reflect events after the date of this release.
Media Contacts
Karin Gerbens
gerbens_karin@elanco.com
+32 476 978 467
Rachel Reiff
rreiff@aratana.com
+1 (913) 353-1050
View original
content:http://www.prnewswire.com/news-releases/elanco-aratana-announce-positive-opinion-on-galliprant-grapiprant-tablets-in-europe-300553682.html
SOURCE Aratana Therapeutics, Inc.